Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Cell Carcinoma (RCC): early-phase trial registry
7 of 13 indexed Renal Cell Carcinoma (RCC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 7 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Renal Cell Carcinoma (RCC): 13 US clinical trials tracked, 7 recruiting.
Renal Cell Carcinoma (RCC) is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Ciprian Catana, MD, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition renal-cell-carcinoma-rcc
OPEN 7 | RECR 54% | LATE 3 | EARLY 5 | RANK #1315 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Advanced Renal Cell Carcinoma (54% recruiting · 13 trials)
Renal Cell Carcinoma (RCC) lists 7 open slots (54% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Cell Carcinoma (RCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Cell Carcinoma (RCC) is recruiting above its size-band peers.
7 of 13 indexed trials (53.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Renal Cell Carcinoma (RCC) trials is spread across many organizations.
Ciprian Catana, MD, PhD accounts for 1 of 13 trials (7.7%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Renal Cell Carcinoma (RCC) enrolment sits around 118 participants.
Median target enrolment is 118 among the 13 trials that report a genuine target (sentinel values excluded). 5 of those (38.5%) plan for fewer than 100 participants.
-
Renal Cell Carcinoma (RCC) research is mostly interventional.
11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology
NCT06661720
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation
NCT05824975
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT06332755
ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
University of Florida
NCT06722807
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
University of Alabama at Birmingham
NCT05410509
Investigation of Lymph Node Biology in Kidney Cancer
Yale University
NCT07038733
Multimodal Machine Learning Characterization of Solid Tumors
Ciprian Catana, MD, PhD
NCT04687969
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03634540
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
Ohio State University Comprehensive Cancer Center
NCT06630429
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad
NCT03647163
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Novartis Pharmaceuticals
NCT01235962
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
NCT03260894
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Cell Carcinoma (RCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Cell Carcinoma (RCC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Cell Carcinoma (RCC) page
13 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Renal Cell Carcinoma (RCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ciprian Catana, MD, PhD sponsors the most Renal Cell Carcinoma (RCC) trials on record, review their full trial history before evaluating a specific study. See Ciprian Catana, MD, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Cell Carcinoma (RCC) condition card totals 13 registered trials; most-linked intervention Pembrolizumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.